Lenvatinib and Lenalidomide Approved, New Agent Promising in Myeloma, and More

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

A new life-years-saved methodology found blood cancer treatments saved million years of life since 1949, with future gains reliant on funding and access.

Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.

Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.

JBS-003 will be evaluated in an ongoing phase 3 trial designed to determine whether investigators can identify patients who can safely receive less radiation.

Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.

The FDA approved daraxonrasib for pancreatic cancer, cleared zanidatamab-based regimens for HER2-positive gastric cancer, and more.

An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.